ClinicalTrials.gg
CompletedNCT04579159Smart in OACUpdated Jul 7, 2022

The Smartphone and Wearable Detected Atrial Arrhythmia in Older Adults Case Finding Study (Smart in OAC - AFNET 9)

An interventional study of Preventicus heartbeat app in combination with wearables in Atrial Arrhythmia, sponsored by Atrial Fibrillation Network. Completed at 4 sites in 3 countries. Open to participants aged 65 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-07-07.

Sponsored by Atrial Fibrillation Network · Not applicable, Interventional, and Screening

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
882
Allocation
Not applicable
Ages
65 Years and older
Sex
All
01

Study summary

This feasibility study will develop and evaluate pathways to identify participants with wearable-detected absoulute Arrhythmia (AA) and to enable local study teams to contact them regarding participation in a controlled trial of oral anticoagulation in this population, which will be conducted after the feasibility study.

Read the detailed description

In this study, the feasibility of evaluating the efficacy of a cloud based analytic service in combination with a PPG-wearable in detecting AA will be assessed and the number of cases found. The design aims to provide simple, low-threshold access to this screening technology targeting at-risk populations. This study will not cause any restrictions on the usual care of the study participants. Access to the screening will be provided close to home and free of charge. The app will also be used to validate and enhance the clinical information about the participants captured during the study. This information will be used to define and refine target groups with highest screening efficiency and, in the long-term, outcome benefits. The study will describe the prevalence of AA in an unselected population that can be reached by a low-threshold screening procedure. The study will also generate important information on the different possible screening environments in different countries (e.g. pharmacies, GP practices, etc). Structures of work-up and continuous patient management in screen-positive individuals will be described and may help to design screening pathways in the main trial. By verifying the wearable-diagnoses by ECG in all screen-positive and a random selection of screen-negative participants, the diagnostic accuracy of the wearable in combination of cloud based analytic service can be estimated. Cost effectiveness assessment will evaluate the cost of low-threshold remote screening per patient identified and help guide to target high risk groups with optimal screening yield in the future. The collected data will provide the sound basis for the design and conduct of a large outcome trial.

02

Conditions studied

  • Atrial Arrhythmia
03

In context

Lead sponsor

Atrial Fibrillation Network is the lead sponsor of 14 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

Inclusion criteria:

  • 65 years or older
  • Willing and able to provide
  • Owning mobile phone compatible with the PPG-wearable

Exclusion criteria:

  • Known AF
  • Known current or planned oral anticoagulation treatment
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
882 participants (actual)

Study arms

  • Other
    only control group

    To investigate the specificity of the wearable and to gather more information on ECG abnormalities in the population studied, a randomly selected group of participants without wearable-detected AA within 8 weeks of screening (same number as screen-positives and verified by Telecare) will also be invited to obtain a 14day Tele ECG (patch).

    Device: Preventicus heartbeat app in combination with wearables

Interventions

  • DevicePreventicus heartbeat app in combination with wearables

    CE certified devices

06

What researchers measure

Primary outcomes

  1. Proportion of participants with newly detected AA within 4 weeks of device use of all participants included in the study

    Proportion of participants with newly detected AA within 4 weeks of device use of all participants included in the study

    Time frame: Screening per participant: 4-8 weeks

Secondary outcomes

  1. Propotion of participants with AA detected at any time, including those with AA detected within the full time of recording

    Propotion of participants with AA detected at any time, including those with AA detected within the full time of recording

    Time frame: Screening per participant: 4-8 weeks ECG screening: 2 weeks Overall study duration: 12 months

  2. Time from completed enrolment to the first positive screening, taking death as compeeting risk into account

    Time from completed enrolment to the first positive screening, taking death as compeeting risk into account

    Time frame: Screening per participant: 4-8 weeks ECG screening: 2 weeks Overall study duration: 12 months

  3. Regional differences of AA prevalance (diagnostic yield)

    Regional differences of AA prevalance (diagnostic yield)

    Time frame: Screening per participant: 4-8 weeks ECG screening: 2 weeks Overall study duration: 12 months

  4. Differences by rout fo invitation and enrolment

    Differences by rout fo invitation and enrolment

    Time frame: Screening per participant: 4-8 weeks ECG screening: 2 weeks Overall study duration: 12 months

  5. Duration of atrial arrhythmia episodes

    Duration of atrial arrhythmia episodes will be reported descriptively by mean, sd, range, median and IQR

    Time frame: Screening per participant: 4-8 weeks ECG screening: 2 weeks Overall study duration: 12 months

  6. Follow-up EQ-5DL-5L viscual analogue scale of participants with positve PPG

    Follow-up EQ-5DL-5L viscual analogue scale of participants with positve PPG

    Time frame: Screening per participant: 4-8 weeks ECG screening: 2 weeks Overall study duration: 12 months

  7. Detection of AF: Number of participants with clinically confirmed arrhythmias during Holter ECG

    Detection of AF: Number of participants with clinically confirmed arrhythmias during Holter ECG, documented clinically or by event-recorder

    Time frame: Screening per participant: 4-8 weeks ECG screening: 2 weeks Overall study duration: 12 months

  8. Compliance: The compliance of participants with protocol with regards to the measurement procedure of the app and wearable

    Compliance: The compliance of participants with protocol with regards to the measurement procedure of the app and wearable will be presented descriptively

    Time frame: Screening per participant: 4-8 weeks ECG screening: 2 weeks Overall study duration: 12 months

07

Study locations

4 sites
  • Universitäres Herz- und Gefäßzentrum UKE Hamburg
    Hamburg, Germany
  • Kardiologische Praxis, Dr. med. Jens Taggeselle
    Markkleeberg, 04416, Germany
  • Krakowskie Centrum Diagnostyczno-Kliniczne (KCDK)
    Kraków, 31-514, Poland
  • Hospital Clínic Unitat d'Arrítmies, Institut Cardiovascular
    Barcelona, Catalonia 08036, Spain
08

References and documents

Publications

  • Fabritz L, Connolly D, Czarnecki E, Dudek D, Zlahoda-Huzior A, Guasch E, Haase D, Huebner T, Jolly K, Kirchhof P, Schotten U, Zapf A, Schnabel RB. Remote Design of a Smartphone and Wearable Detected Atrial Arrhythmia in Older Adults Case Finding Study: Smart in OAC - AFNET 9. Front Cardiovasc Med. 2022 Mar 21;9:839202. doi: 10.3389/fcvm.2022.839202. eCollection 2022. PubMed 35387433 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2021 to primary completion in Feb 2022, 12 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 8, 2020
First posted
Oct 8, 2020
StartActual
Jan 26, 2021
Primary completionActual
Feb 25, 2022
CompletionActual
Feb 25, 2022
Last update
Jul 7, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 7, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04579159
Lead sponsor
Atrial Fibrillation Network
Collaborators
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company, Preventicus GmbH, Corsano/ MMT, Getemed Medizin- und Informationstechnik
Responsible party
Sponsor
First posted
Oct 8, 2020
Start date
Jan 26, 2021
Primary completion
Feb 25, 2022
Completion
Feb 25, 2022
Last update
Jul 7, 2022

Study contacts

Larissa Fabritz, Professor
principal investigator · Institute of Cardiovascular Sciences, University of Birmingham

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion